Parkinson disease is a neurological disorder that affects movement, muscle control, and balance. Parkinson disease most commonly affects people ages 55 to 75 years, but it can also develop in younger people. The disease is progressive, with symptoms becoming more severe over time.
Parkinson disease may be difficult to diagnose in its early stages. The disease is generally diagnosed on the basis of symptoms, which may include:
There is no cure for Parkinson disease. Treatments focus on controlling symptoms and improving quality of life.
Parkinson disease (PD) is a slowly progressive neurological disorder that affects movement, muscle control, and balance. Parkinson disease is part of a group of conditions called motor system disorders, which are associated with the loss of dopamine-producing brain cells. The term "parkinsonism" refers to these dopamine-associated motor disorders, which include Parkinson disease.
Parkinson disease occurs from the following process in the brain:
Parkinson disease is a slowly progressive disorder that affects movement, muscle control, and balance.
Dopamine deficiency results in the hallmark features of PD. Dopamine is one of three major neurotransmitters known as
Loss of dopamine impairs the nerves and muscles controlling movement and coordination, resulting in the major symptoms of Parkinson disease. Dopamine also appears to be important for efficient information processing. Dopamine deficiencies may be responsible for the problems in memory and concentration that affect many people with Parkinson.
Doctors don't know what causes Parkinson disease. A combination of genetic and environmental factors likely plays a role.
Specific genetic factors appear to play a strong role in early-onset Parkinson disease, an uncommon form of the disease. Multiple genetic factors may also be involved in some cases of late-onset Parkinson disease.
Environmental factors are probably not a sole cause of Parkinson disease, but they may trigger the condition in people who are genetically susceptible.
Some evidence implicates pesticides and herbicides as possible factors in some cases of Parkinson disease. A higher incidence of parkinsonism has long been observed in people who live in rural areas, particularly those who drink private well water or are agricultural workers.
The average age of onset of Parkinson disease is 55. About 10% of Parkinson cases are in people younger than age 40. Older adults are at higher risk for both parkinsonism and Parkinson disease.
Parkinson disease is more common in men than in women.
People with siblings or parents who developed Parkinson at a younger age face an increased risk for the condition. However, relatives of patients who developed Parkinson at an older age appear to have an average risk.
African Americans and Asian Americans appear to have a lower risk than Caucasians.
Both smoking and coffee drinking are associated with a lower risk for PD.
Cigarette smokers appear to have a lower risk for Parkinson disease, indicating possible protection by nicotine. This finding is, of course, no excuse to smoke. The few studies on nicotine replacement as a treatment for Parkinson have not provided any strong evidence that nicotine therapy provides benefits.
Some studies suggest that the risk for PD in coffee drinkers is lower than for non-coffee drinkers.
Parkinson disease (PD) is not fatal, but it can reduce longevity. The disease progresses more quickly in older people, and it may lead to severe incapacity within 10 to 20 years. Older people with PD also tend to have muscle freezing and greater declines in mental function and daily functioning than younger people. If PD starts without signs of tremor, it is likely to be more severe than if tremor is present.
Parkinson disease can seriously impair the quality of life in any age group. In addition to motor symptoms (motion difficulties, tremors), Parkinson can cause various non-motor problems that have significant physical and emotional impacts on patients and their families.
Swallowing problems (dysphagia) are sometimes associated with shorter survival time. Loss of muscle control in the throat not only impairs chewing and swallowing, which can lead to malnourishment, but also poses a risk for aspiration pneumonia. Swallowing problems can also interfere with adequate consumption of fiber and fluid, which can worsen constipation.
Depression is very common in people with Parkinson. The disease process itself causes changes in brain chemicals that affect mood and well-being. Anxiety is also very common and may present along with depression.
Some drug treatments, particularly dopamine agonists, can cause poor impulse control and compulsive behaviors, such as gambling, shopping, and increased sexuality. People who have pre-existing tendencies for novelty-seeking behavior, or a family or personal history of alcohol abuse, may be more likely to develop these problems. Deep brain stimulus (DBS) surgery may also increase the risk for compulsive gambling in people who have a history of gambling.
Defects in thinking, language, and problem solving skills may occur early on or later in the course of the disease. These problems can arise from the disease process or from side effects of medications used to treat Parkinson. People with PD are slower in detecting associations, although (unlike in Alzheimer disease) once they discover them they are able to apply this knowledge to other concepts.
Dementia occurs in about two-thirds of people with Parkinson, especially those who developed PD after age 60. Dementia is the significant loss of cognitive functions such as memory, judgment, attention, and abstract thinking. It is most likely to occur in older people who have had major depression. PD marked by muscle rigidity (akinesia) rather than tremor, and early hallucinations also increase the risk for dementia. (Visual hallucinations can also occur as a side effect of dopamine medication.) Unlike Alzheimer disease, language is not usually affected in Parkinson-related dementia.
Excessive daytime sleepiness, insomnia, and other sleep disorders are common in PD, both from the disease itself and the drugs that treat it. Bladder problems can also contribute to sleep disturbances. Many people with Parkinson disease also suffer from nighttime leg cramps and restless legs syndrome. Some of the medications used for PD may cause vivid dreams, as well as waking hallucinations.
Although Parkinson disease and its treatments can cause compulsive sexual behavior, the disease can also cause a loss of sexual desire in both men and women. For men, erectile dysfunction can be a complication of Parkinson.
Constipation is a common complication of Parkinson disease. It is often caused by muscle weakness that can slow down the action of the digestive system. Weakness in pelvic floor muscles can also make it difficult to defecate. In addition, swallowing problems associated with muscle weakness may make it difficult to eat enough fiber-rich foods and drink enough fluids, which can also cause constipation. Constipation may also occur as a side effect of some Parkinson medications.
People with Parkinson disease may experience urinary incontinence, including increased urge and frequency, although this is less common than constipation. PD can also cause urinary retention (incomplete emptying of the bladder).
Orthostatic hypotension is a rapid drop in blood pressure (hypotension is the medical term for low blood pressure) triggered by a sudden change in body position. It usually occurs when standing up after sitting or lying down.
Parkinson disease, and the medications used to treat it, can also cause orthostatic hypotension. Lifestyle factors that can contribute to orthostatic hypotension include dehydration, alcohol, hot drinks and foods, and overexertion.
Symptoms of orthostatic hypotension include dizziness, lightheadedness, weakness, blurred vision, loss of balance, and fainting. Orthostatic hypotension can increase the risk for falls and injuries, and limit patients' ability to perform daily tasks that require standing or walking.
Many people with PD experience an impaired sense of smell.
Vision may be affected, including impaired color perception and contrast sensitivity.
Painful symptoms associated with Parkinson disease include back pain, neck pain, tingling, and aching. Pain in Parkinson often results from dystonia (involuntary muscle contractions and spasms that can cause twisting and jerking), as well as from the gastrointestinal system.
People with PD often develop skin problems, including excessively oily, dry, or flaking skin. Of greatest concern, Parkinson disease appears to be associated with a higher risk for developing melanoma (an aggressive skin cancer). People with Parkinson disease should have regular screenings with a dermatologist to check for skin changes that may indicate melanoma.
Parkinson disease (PD) symptoms often start with tremor, which may occur in the following ways:
About 25% of patients with PD do not develop tremor.
Many PD symptoms involve motor impairment caused by problems in the brain nerves that regulate movement:
Parkinson disease also causes non-motor symptoms, including fatigue, sleep problems, gastrointestinal and urinary disorders, sexual dysfunction, decreased sense of smell, and depression and anxiety. [See
Sialorrhea (drooling) is a common and bothersome symptom for those with Parkinson disease. It can cause chapped lips and skin around the mouth, dehydration, an unpleasant odor, and social embarrassment.
Parkinson disease (PD) can be difficult to diagnose in its early stages. Doctors base their diagnosis on the person's medical history and symptoms evaluated during a neurological exam.
Brain scans such as computed tomography (CT), magnetic resonance imaging (MRI), or positron-emission tomography (PET) may be used to rule out other neurological disorders. Genetic tests may be used to identify inherited forms of PD.
A medical and personal history should include any relevant symptoms, as well as any medications taken, and information on other conditions the person may have.
In a neurological exam, the doctor will ask you to sit, stand, walk, and extend your arms. The doctor will observe your balance and coordination. PD may be suspected in people who have at least 2 of the following 4 symptoms, especially if they are more obvious on one side of the body:
A levodopa challenge test may confirm a diagnosis of Parkinson disease. If your symptoms improve when you take the drug levodopa, you likely have Parkinson, and not another type of neurological disease.
The American Academy of Neurology (AAN) recommends the Beck Depression Inventory or the Hamilton Depression Rating Scale to screen for depression in patients with Parkinson disease. The AAN recommends the Mini Mental State Examination (MMSE) and Cambridge Cognitive Examination (CAMCOG) tests to screen for dementia. During these tests, the patient answers a series of questions.
Parkinson disease is the most common type of parkinsonism. Parkinsonism refers to a group of movement disorders that share similar symptoms with Parkinson disease, but also have unique symptoms of their own. About 15% of parkinsonism cases are due to conditions called Parkinson plus syndromes (PPS) or atypical parkinsonism. These syndromes include:
People with PPS often have earlier and more severe dementia than those with Parkinson disease. In addition, they do not usually respond to medications that are used to treat Parkinson disease.
Many medical conditions may cause some symptoms of Parkinson disease and parkinsonism. Hardening of the arteries (arteriosclerosis) in the brain can cause multiple small strokes, which can produce loss of motor control. Alzheimer disease can share similar symptoms with Parkinson and the conditions can exist together.
Several drugs, including antipsychotic and antiseizure medications, can cause Parkinson-type symptoms.
There is no cure for Parkinson disease (PD), but drugs, physical therapy, lifestyle changes, and surgical interventions can help control symptoms and improve quality of life.
Treatment for this complicated condition must be individualized. People with PD must work closely with their health care team throughout the course of the disease to tailor a treatment program to their particular and changing needs. No treatment method, including drug therapy, has been proven to change the course of the disease or slow disease progression. But many treatments can help ease symptoms and restore normal functioning for long periods of time.
The decision to start drug therapy usually arises when motor symptoms (movement problems, muscle rigidity, tremors) begin to interfere with daily functioning. The main types of drugs for treating Parkinson disease are:
All of these drugs have side effects. Your health care provider will discuss with you the risks and benefits of various drugs, and will take into consideration such factors as your overall health, age, symptoms, stage of Parkinson disease, and other medical conditions you may have.
In general, levodopa/carbidopa is the standard drug for treating PD throughout its disease course, but other drugs may be used for its earlier stages. When levodopa is used for many years, it can "wear off" and symptom improvement ("on" time) may decrease while symptom worsening ("off" time) increases. Motor symptoms may also fluctuate unpredictably. Your health care provider may adjust the dosage or add another drug to your regimen to help boost levodopa's effectiveness.
For people with advanced Parkinson disease whose symptoms can no longer be controlled by medication, surgical treatment with deep brain stimulation may be an option. (Some recent research suggests this treatment may also be helpful for patients in earlier stages of the disease). Home modifications (wheelchair ramps, grab bars, and handrails) can help improve functional abilities and independent living. Treatment goals for all stages of Parkinson disease should focus on providing safety, comfort, and quality of life.
Conditions associated with non-motor impairment symptoms of Parkinson disease may need a variety of treatments.
Medications for PD-associated depression include older drugs such as the tricyclic antidepressant amitriptyline, as well as newer antidepressants, including selective serotonin-reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) such as fluoxetine (Prozac, generic), sertraline (Zoloft, generic), paroxetine (Paxil, generic), and venlafaxine (Effexor, generic). The dopamine agonist pramipexole (Mirapex, generic) may also be helpful for Parkinson depression. Health care providers need to monitor antidepressants to make sure they do not worsen motor symptoms.
Psychosis in Parkinson disease is often a side effect of medication. Doctors first try to adjust the dose of PD medications to see if psychotic side effects decrease without motor symptoms increasing. In some cases, doctors may prescribe an antipsychotic drug, usually quetiapine (Seroquel, generic). The antipsychotic clozapine (Clozaril, generic) is also effective, but it can have a serious side effect of lowering white blood cell count. Certain types of antipsychotic medications, such as olanzapine (Zyprexa, generic) and risperidone (Risperdal, generic), should not be used in people with PD because they can worsen Parkinson symptoms.
The cholinesterase inhibitor drugs donepezil (Aricept, generic) and rivastigmine (Exelon, generic) are used to treat Alzheimer disease and are sometimes used for Parkinson. (Rivastigmine is FDA-approved for treatment of Parkinson dementia.) These drugs typically have at best a very modest benefit on cognitive function.
Modafinil (Provigil, generic), a drug used to treat narcolepsy, may be helpful for PD-associated sleepiness. Methylphenidate (Ritalin, generic) may be considered for treating fatigue.
PDE5 inhibitor drugs such as sildenafil (Viagra), tadalafil (Cialis), vardenafil (Levitra), and avanafil (Stendra) can be helpful for men with Parkinson disease who suffer from erectile dysfunction. However, these drugs may worsen orthostatic hypotension.
Orthostatic hypotension is a sudden drop in blood pressure that occurs when rising from a sitting or lying down position. It causes dizziness and light-headedness. Lifestyle treatments include avoiding dehydration, carbohydrate-heavy meals, overexposure to heat, and vigorous exercise. Droxidopa (Northdera) is a new drug approved to treat orthostatic hypotension associated with Parkinson disease and other nervous system disorders. Droxidopa and similar medications have a risk of increasing blood pressure when lying down. People who take this drug must be sure to sleep with their head and upper body elevated.
Dietary changes should be the first step for addressing constipation. It is important to increase overall fiber and fluid consumption, but this can be difficult for people who have swallowing problems. Taking a stool softener such as docusate (Colace, generic) on a daily basis may help with bowel movements.
For people who need laxatives, bulk-forming fiber laxatives are considered the safest and are not habit-forming. They include psyllium (Metamucil, other brands, generic) and wheat dextrin (Benefiber, generic). Stimulant laxatives should be avoided as they can worsen bowel problems if used on a long-term basis. Check with your health care provider for advice about using other types of laxatives, suppositories, and enemas. Regular exercise is also helpful for constipation.
Glycopyrrolate, scopolamine, and injections of botulinum toxin may be used to relieve drooling symptoms.
Levodopa, also called L-dopa, which is converted to dopamine in the brain, remains the gold standard for treating Parkinson disease (PD) symptoms. The standard preparations (Sinemet, Parcopa) combine levodopa with carbidopa, which improves the action of levodopa and reduces some of its side effects, particularly nausea. Sinemet is swallowed as a pill. Parcopa is a tablet that dissolves under the tongue.
Dosages vary, although the preparation is usually taken in 3 or 4 divided doses per day. This medication works best on an empty stomach, but some people find this causes nausea and prefer to take it with a light meal or snack. If you are taking levodopa/carbidopa along with food, it is important to avoid high-protein foods as they can interfere with drug absorption.
Levodopa/carbidopa helps improve mobility for many people with PD. It works best for treating difficulties with movement (akinesia) and muscle stiffness. It may be less effective for treating tremor, balance, coordination, and posture.
Levodopa/carbidopa does not prevent Parkinson disease progression. Over time, the dose of the drug has to be increased to be effective.
Many side effects of levodopa/carbidopa can be minimized by adjusting dosage. The most common side effects include nausea, vomiting, loss of appetite, low blood pressure, dizziness, and confusion.
Serious side effects include:
After several years of taking levodopa, many people with PD find that the drug's helpful effects last for shorter periods of time and that symptoms return before the next dose is due to be taken. When the medication wears off in between doses, symptoms may suddenly worsen ("off-time"). At other times of the day, symptoms may be well-controlled ("on-time"). Wearing off can develop gradually during the day, or it can occur intermittently and unpredictably.
An increase in dyskinesia (involuntary movements) and other motor symptoms (muscle stiffness, rigidity, slowness, cramping) are most commonly associated with the wearing-off effect. Some people may also experience non-motor symptoms, such as difficulty concentrating, anxiety, insomnia, fatigue, sweating, and trouble breathing. If symptoms improve when the next dose of levodopa/carbidopa is taken, this is a clear sign of the wearing-off effect.
There are different approaches for managing wearing off and off-time. Your doctor may recommend:
Making some adjustments to your food schedule may also help with wearing off. Try to take levodopa/carbidopa on an empty stomach, at least 30 minutes before eating. High-protein foods can especially interfere with levodopa absorption.
Levodopa is converted into dopamine in the brain. In contrast, dopamine agonists mimic the action of dopamine by stimulating dopamine receptors in the brain. A dopamine agonist drug may be used as an initial medication in the early stages of PD to delay the need for levodopa, or it may be used along with levodopa/carbidopa in later stages of the disease.
When used alone, these drugs are less likely to cause dyskinesia than levodopa, but they may be less effective than levodopa for controlling motor symptoms. There is debate about the value of dopamine agonists as first-line therapy for Parkinson disease. Some research suggests that early treatment with dopamine agonists may not provide any long-term advantages compared with starting treatment with levodopa/carbidopa.
Pramipexole (Mirapex, generic) and ropinirole (Requip, generic) are the most commonly prescribed oral dopamine agonists. Rotigotine (Neupro) is a skin patch that is applied once a day. Apomorphine (Apokyn) is a self-injectable dopamine agonist that is used as a rescue medication for quickly treating off-time motor symptoms in advanced PD.
Common side effects of dopamine agonists include nausea, confusion, and leg swelling. More serious concerns include:
MAO-B inhibitor drugs block monoamine oxidase B (MAO-B), an enzyme that inactivates dopamine. Selegiline (Eldepryl, Zelapar) and rasagiline (Azilect) are MAO-B inhibitors used for treating Parkinson disease.
These drugs may be used alone in the early stages of PD to treat mild symptoms (such as tremor) and delay the need for levodopa. They may also be used in combination with levodopa in later stages to enhance the effects of levodopa and help manage motor fluctuations. Rasagiline may also be used in combination with dopamine agonists. Many people with PD notice only small benefits in improvement with these drugs.
Common side effects of MAO-B inhibitors include flu symptoms, dizziness, and insomnia. More serious side effects may include agitation, confusion, and hallucination.
Talk with your health care provider about any other medications (both prescription and over-the-counter) and supplements you are taking. MAO-B inhibitors can interact with a number of medications, including narcotics, pain relievers, cough suppressants, and antidepressants (including the herbal remedy St. John's wort). Foods high in the amino acid tyramine may cause a dangerous increase in blood pressure, particularly if you are taking a high dose of this medicine. Foods to be avoided include processed lunch meats, soy sauce, aged cheeses, and beer.
Catechol-O-methyl transferase (COMT) inhibitor drugs are used along with levodopa/carbidopa to increase and prolong levodopa's effectiveness and prevent wearing off. Entacapone (Comtan, generic) is the standard COMT inhibitor. Stalevo (generic) is a pill that combines entacapone, levodopa, and carbidopa. A third COMT inhibitor, tolcapone (Tasmar), is only rarely prescribed due to its risks for liver damage.
COMT inhibitors are always used in combination with levodopa/carbidopa and may increase levodopa's dyskinesia side effect. Other side effects may include low blood pressure when standing up (orthostatic hypotension), nausea, dizziness, diarrhea, and urine discoloration.
Since 2010, the FDA has been reviewing whether Stalevo may increase the risk of prostate cancer.
Anticholinergics were the first drugs used for PD, but they have largely been replaced by dopamine drugs. They are generally used only to control tremor in the early stages. Among the many anticholinergics are trihexyphenidyl (Artane, Trihexane, generic) and benztropine (Cogentin, generic).
Anticholinergics commonly cause dryness of the mouth (which can actually be an advantage in some people who experience drooling). Other side effects are nausea, urinary retention, blurred vision, and constipation. These drugs can increase heart rate and worsen constipation. Anticholinergics can sometimes cause significant mental problems, including memory loss, confusion, and even hallucinations. People with glaucoma should use these drugs with caution.
Amantadine (generic) stimulates the release of dopamine and may be used to provide temporary relief of early mild symptoms such a tremor and rigidity. It is sometimes prescribed along with levodopa/carbidopa for advanced PD to help control motor fluctuations and dyskinesia.
Side effects are similar to those of anticholinergic drugs, and may include swollen ankles and, in rare cases, mottled skin. Amantadine can also cause visual hallucinations, confusion, and memory loss.
Surgical procedures are recommended for specific individuals with advanced Parkinson disease (PD) whose symptoms are not controlled by drug treatments. Surgical treatment cannot cure Parkinson disease, but it may help control symptoms such as motor fluctuations and dyskinesia.
Deep brain stimulation is the current standard surgical approach for Parkinson disease. It has largely replaced pallidotomy and thalamotomy, older operations that destroy tissue in certain parts of the brain.
In deep brain stimulation (DBS), also called neurostimulation, an electric pulse generator controls symptoms such as severe tremors, wearing-off fluctuations, and dyskinesia. The generator is similar to a heart pacemaker. It sends electrical pulses to specific regions of the brain. Candidates most likely to benefit from DBS are those who have advanced PD, have responded well to levodopa drug treatment, are younger in age, and do not have significant cognitive or psychiatric problems. Some recent research suggests that DBS may also benefit people in earlier stages of the disease who have early signs of motor symptoms.
For treatment of motor symptoms, DBS usually targets one of two areas of the brain: the subthalamic nucleus (STN) or the globus pallidus pars interna (GPi). Research indicates that both areas are equally likely to respond well to DBS. DBS targeting the STN may allow people to use less medication, but treatment of this brain area may worsen depression, apathy, impulsivity, ease of using words, and falls.
For treatment of disabling tremors, DBS may be used to target the STN, GPi, or the ventral intermediate nucleus of the thalamus.
DBS should be performed by an experienced neurosurgeon who is trained in stereotactic neurosurgery (surgery that uses 3-dimensional imaging to help target specific areas of the brain).
The procedure is performed as follows:
The benefits of DBS appear to be long lasting, but it may take 3 to 6 months to achieve results. During this time, doctors may need to adjust the implanted device. Researchers are still trying to determine the best surgical techniques for implanting the DBS device, and how to best select the people who are most likely to benefit.
Pallidotomy and thalamotomy are surgical procedures that destroy brain tissue in regions of the brain associated with Parkinson symptoms such as dyskinesia, rigidity, and tremor. In these procedures, a surgeon drills a small hole in the patient's skull and inserts an electrode to destroy brain tissue. Pallidotomy targets the global pallidus area. Thalamotomy targets the thalamus. Because these procedures permanently eliminate brain tissue, most doctors now recommend deep brain stimulation instead of pallidotomy or thalamotomy.
Surgical complications may include behavioral or personality changes, trouble speaking and swallowing, facial paralysis, and vision problems. Weight gain after surgery is also common.
Scientists are investigating whether stem cells may eventually help treat Parkinson disease. Experimental surgery has shown promise using fetal brain cells rich in dopamine implanted in the substantia nigra area of the brain. Because the use of embryonic stem cells is controversial, researchers are studying alternative types of cells, including stem cells from adult brains and cells from human placentas or umbilical cords. All of this research is still preliminary.
No special diets or foods can slow the progression of Parkinson disease (PD), but certain dietary strategies may help manage symptoms.
High levels of protein can affect how much levodopa can reach the brain and can reduce the drug's effectiveness. Avoiding protein altogether is not the solution, since malnutrition can result. Most health care providers recommend reducing protein or eating most of your protein at the evening meal. Discuss a low-protein diet and other nutritional strategies with your health team.
Good control of protein intake may help minimize fluctuations and wearing-off, and allow some people with PD to reduce their daily levodopa dosage.
Eating whole grains, fresh fruits, and vegetables is the best approach for any healthy life. A diet rich in fruits and vegetables may help protect nerve cell function. Many of these foods are also rich in fiber, which is particularly important for helping to prevent constipation.
Dietary fiber is the part of food that is not affected by the digestive process in the body. Only a small amount of fiber is metabolized in the stomach and intestine. The rest is passed through the gastrointestinal tract and makes up part of the stool. There are two types of dietary fiber, soluble and insoluble. Soluble fiber retains water and turns to gel during digestion. It also slows digestion and nutrient absorption from the stomach and intestine. Soluble fiber is found in foods such as oat bran, barley, nuts, seeds, beans, lentils, peas, and some fruits and vegetables. Insoluble fiber appears to speed the passage of foods through the stomach and intestines and adds bulk to the stool. It is found in foods such as wheat bran, vegetables, and whole grains. One of the best sources of fiber comes from legumes, the group of foods containing dried peas and beans.
If you are used to eating a low-fiber diet, you should try to gradually increase the amount of fiber. It is best to obtain dietary fiber, soluble or insoluble, in the natural form of whole grains, nuts, legumes, fruits, and vegetables. If it proves difficult to do so, psyllium (found in products such as Metamucil) is an excellent soluble fiber supplement. Drinking lots of fluids is particularly important for preventing constipation.
For reasons that are not completely understood, many people with PD experience weight loss. Parkinson disease can affect a person's sense of smell and taste, which may make food less appetizing. Tremors (shaking) and swallowing problems can make it more difficult and tiring to eat. If you find that you are losing weight without trying, talk with your health care provider or dietitian about developing a diet plan that will meet your caloric needs.
There is currently no evidence for the effectiveness of any herb or dietary supplement in the treatment of Parkinson disease. Coenzyme Q10 is the most-studied supplement for early-stage PD. Clinical trials have failed to show it has any benefits.
Ginger is one natural remedy that has well-established properties for easing nausea. A simple tea made from boiling ginger root may help alleviate nausea symptoms associated with many Parkinson disease medications.
Let your health care provider know about any herb or dietary supplement you are taking, or considering taking. Some products, such as St. John's wort, can interact and interfere with the effectiveness of Parkinson medications.
Regular exercise is important for people in all stages of Parkinson disease. Exercise has a wide range of benefits. It can improve muscle strength and agility, which helps promote better walking and balance. Exercise can also help control symptoms such as fatigue, constipation, and depression.
Health care providers recommend that people with PD incorporate stretching, resistance, and aerobic exercise into their routine. Some suggestions include:
Try to practice regular daily activities that simplify actions and reduce the incidence of muscle freezing. Most often, freezing occurs when a person with PD begins to move or is presented with an obstacle. The following tips may be helpful:
Practicing new methods for standing, walking, and turning may help retain balance and reduce the risk of falls. The following tips may be helpful:
People with PD can benefit from working with rehabilitative therapists. They include physical therapy, occupational therapy, and speech therapy. Art therapies (including dance therapy and music therapy) may also be helpful.
Exercise is an important component of rehabilitation. Physical therapy can help with physical function and quality of life. It usually includes active and passive exercise, gait training, and practice in normal activities. A physical therapist can help with passive exercise, stretching and manipulating muscles to help prevent deterioration and shortening. Active exercises are used to help range-of-motion, coordination, and speed. A physical therapist can also advise on how to best use mobility aids (such as canes, crutches, and scooters) and other assistive devices.
Speech therapy may help those who develop a monotone voice and lose volume. Certain techniques, such as the Lee Silverman Voice Technique, are designed specifically to help people with Parkinson disease speak louder. A speech therapist can also help evaluate and monitor swallowing issues.
Occupational therapists help people learn how to improve their functioning and independence within their home and workplace environments. They can help people better manage activities of daily living, including bathing, dressing, and grooming. Occupational therapists can provide professional advice on what sort of adaptive tools, such as grab bars, should be used in the bathroom, bedroom, and kitchen. They can advise on mobility devices such as wheelchairs and scooters.
Relaxation techniques and staying mentally active are important for managing stress and dealing with feelings of depression and anxiety:
National Institute of Neurological Disorders and Stroke -- www.ninds.nih.gov
American Academy of Neurology -- www.aan.com
American Parkinson Disease Association -- www.apdaparkinson.org
Parkinson's Disease Foundation -- www.pdf.org
The Michael J. Fox Foundation for Parkinson's Research -- www.michaeljfox.org
Parkinson's Action Network -- www.parkinsonsaction.org
Canning CG, Sherrington C, Lord SR, et al. Exercise for falls prevention in Parkinson disease: a randomized controlled trial. Neurology. 2015;84(3):304-312. PMID: 25552576 www.ncbi.nlm.nih.gov/pubmed/25552576.
Connolly BS, Lang AE. Pharmacological treatment of Parkinson disease: a review. JAMA. 2014;311(16):1670-1683. PMID: 24756517 www.ncbi.nlm.nih.gov/pubmed/24756517.
Elbers RG, Verhoef J, van Wegen EE, Berendse HW, Kwakkel G. Interventions for fatigue in Parkinson's disease. Cochrane Database Syst Rev. PMID: 26447539 www.ncbi.nlm.nih.gov/pubmed/26447539.
Fasano A, Visanji NP, Liu LW, Lang AE, Pfeiffer RF. Gastrointestinaldysfunction in Parkinson's disease. Lancet Neurol. 2015;14(6):625-639. PMID: 25987282 www.ncbi.nlm.nih.gov/pubmed/25987282.
Goetz CG, Pal G. Initial management of Parkinson's disease. BMJ. 2014;349:g6258. PMID: 25527341 www.ncbi.nlm.nih.gov/pubmed/25527341.
Hauser RA, Isaacson S, Lisk JP, Hewitt LA, Rowse G. Droxidopa forshort-term treatment of symptomatic neurogenic orthostatic hypotension inParkinson's disease (nOH306B). Mov Disord. 2015;30(5):646-654. PMID: 25487613 www.ncbi.nlm.nih.gov/pubmed/25487613.
Jankovic J. Parkinson disease and other movement disorders. In: Daroff RB, Jankovic J, Mazziotta JC, Pomeroy SL, eds. Bradley's Neurology in Clinical Practice. 7th ed. Philadelphia, PA: Elsevier; 2016:chap 96.
Kaufmann H, Freeman R, Biaggioni I, et al, NOH301 Investigators. Droxidopa for neurogenic orthostatic hypotension: a randomized, placebo-controlled, phase 3 trial. Neurology. 2014;83(4):328-335. PMID: 24944260 www.ncbi.nlm.nih.gov/pubmed/24944260.
Lang AE. Parkinsonism. In: Goldman L, Schafer AI, eds. Goldman's Cecil Medicine. 25th ed. Philadelphia, PA: Elsevier Saunders; 2016:chap 409.
Lang AE. Parkinsonism. In: Goldman L, Ausiello D, eds. Cecil Textbook of Medicine. 3rd ed. Philadelphia, PA: Elsevier Saunders; 2011:chap 41.
Leung IH, Walton CC, Hallock H, Lewis SJ, Valenzuela M, Lampit A. Cognitive training in Parkinson disease: A systematic review and meta-analysis. Neurology. 2015;85(21:1843-1851. PMID: 26519540 www.ncbi.nlm.nih.gov/pubmed/26519540.
Li F, Harmer P, Fitzgerald K, et al. Tai chi and postural stability in patients with Parkinson's disease. N Engl J Med. 2012;366(6):511-519. PMID: 22316445 www.ncbi.nlm.nih.gov/pubmed/22316445.
Odekerken VJ, Boel JA, Schmand BA, et al. GPi vs STN deep brain stimulation for Parkinson disease: Three-year follow-up. Neurology. 2016;86(8):755-761. PMID: 26819458 www.ncbi.nlm.nih.gov/pubmed/26819458.
Pahwa R, Tanner CM, Hauser RA, et al. Amantadine extended release for levodopa-induced dyskinesia in Parkinson's disease (EASED Study). Mov Disord. 2015;30(6):788-795. PMID: 25650051 www.ncbi.nlm.nih.gov/pubmed/25650051.
Parkinson Study Group QE3 Investigators, Beal MF, Oakes D, et al. A randomized clinical trial of high-dosage coenzyme Q10 in early Parkinson disease: no evidence of benefit. JAMA Neurol. 2014;71(5):543-552. PMID: 24664227 www.ncbi.nlm.nih.gov/pubmed/24664227.
Parkinson Study Group QE3 Investigators, Beal MF, Oakes D, et al. A randomized clinical trial of high-dosage coenzyme Q10 in early Parkinson disease: no evidence of benefit. JAMA Neurol. 2014;71(5):543-552. PMID: 24664227 www.ncbi.nlm.nih.gov/pubmed/24664227.
PD Med Collaborative Group, Gray R, Ives N, et al. Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson's disease (PD MED): a large, open-label, pragmatic randomised trial. Lancet. 2014;384(9949):1196-1205. PMID: 24928805 www.ncbi.nlm.nih.gov/pubmed/24928805.
Schlenstedt C, Paschen S, Kruse A, Raethjen J, Weisser B, Deuschl G. Resistance versus balance training to improve postural control in Parkinson's Disease: A randomized rater blinded controlled Study. PLoS One. 2015;10(10). PMID: 26501562 www.ncbi.nlm.nih.gov/pubmed/26501562.
Schuepbach WM, Rau J, Knudsen K, et al. Neurostimulation for Parkinson's disease with early motor complications. N Engl J Med. 2013;368(7):610-622. PMID: 23406026 www.ncbi.nlm.nih.gov/pubmed/23406026.
Shulman LM, Katzel LI, Ivey FM, et al. Randomized clinical trial of 3 types of physical exercise for patients with Parkinson disease. JAMA Neurol. 2013;70(2):183-190. PMID: 23128427 www.ncbi.nlm.nih.gov/pubmed/23128427.
Tomlinson CL, Patel S, Meek C, et al. Physiotherapy intervention in Parkinson's disease: systematic review and meta-analysis. BMJ. 2012;345:e5004. PMID: 22867913 www.ncbi.nlm.nih.gov/pubmed/22867913.
Reviewed By: Amit M. Shelat, DO, FACP, Attending Neurologist and Assistant Professor of Clinical Neurology, SUNY Stony Brook, School of Medicine, Stony Brook, NY. Review provided by VeriMed Healthcare Network. Also reviewed by David Zieve, MD, MHA, Isla Ogilvie, PhD, and the A.D.A.M. Editorial team.